Moreover, we discussed the prognostic value of NUTF2 in HNSCC by DFS analysis, which excludes patients who survive but relapse with HNSCC, offering patients a direct clinical benefit on tumor recurrence and can be a more valuable survival index. This evidence concerns the gene NUTF2 and head and neck squamous cell carcinoma.